throbber
Trials@uspto.gov
`571-272-7822
`
`
`
`
`
` Paper 58
`
`
` Entered: June 21, 2016
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`LUPIN LTD., LUPIN PHARMACEUTICALS INC., INNOPHARMA
`LICENSING, INC., INNOPHARMA LICENSING LLC, INNOPHARMA
`INC., INNOPHARMA LLC, MYLAN PHARMACEUTICALS INC., and
`MYLAN INC.,
`
`Petitioners,
`v.
`
`SENJU PHARMACEUTICAL CO., LTD.,
`
`Patent Owner.
`____________
`
`Case IPR2015-01097 (Patent 8,754,131 B2)1
`Case IPR2015-01100 (Patent 8,927,606 B1)2
` Case IPR2015-01105 (Patent 8,871,813 B2)3
`____________
`
`Before FRANCISCO C. PRATS, ERICA A. FRANKLIN, and
`GRACE KARAFFA OBERMANN, Administrative Patent Judge.
`
`FRANKLIN, Administrative Patent Judge.
`
`DECISION4
`Denying Patent Owner’s Motion to Seal and Denying Entry of
`the Amended Proposed Stipulated Protective Order
`37 C.F.R. §§ 42.14 and 42.54
`
`
`
` 1
`
` Case IPR2016-00089 has been joined with this proceeding.
`2 Case IPR2016-00091 has been joined with this proceeding.
`3 Case IPR2016-00090 has been joined with this proceeding.
`4 This Decision relates to and shall be filed in each referenced case.
`
`

`

`IPR2015-01097 (Patent 8,754,131 B2)
`IPR2015-01100 (Patent 8,927,606 B1)
`IPR2015-01105 (Patent 8,871,813 B2)
`
`
`I.
`
`INTRODUCTION
`
`In each of the captioned proceedings, Patent Owner filed a combined
`
`Motion to Seal and Motion to Enter Stipulated Protective Order. Paper 265
`
`(“Mot.”). Thereafter, Petitioners and Patent Owner jointly filed, in each
`
`proceeding, an Amended Proposed Stipulated Protective Order (“proposed
`
`order”), Paper 29, to add the joined Petitioners InnoPharma Licensing, Inc.,
`
`InnoPharma Licensing LLC, InnoPharma Inc., and InnoPharma LLC to the
`
`caption, see Paper 26, 15 n.2 (explaining that the Stipulated Protective Order
`
`would be refiled after joinder). This Decision addresses Patent Owner’s
`
`Motion to Seal (Paper 26) and the jointly filed proposed order (Paper 29).
`
`Patent Owner seeks to seal the following exhibits and papers: the
`
`entirety of excerpts from Patent Owner’s New Drug Application (“NDA”)
`
`(Exs. 2096, 2102, 2103, 2110, 2251, and 2291–2293); three presentations
`
`related to Patent Owner’s research and development of the patented
`
`formulation (Exs. 2220, 2226, and 2296); testimony related to the market
`
`share of Patent Owner’s product in a related district court case (Ex. 2258);
`
`testing reports and materials documenting the testing methods of third-party
`
`test companies (Exs. 2267–2278, 2286, 2294); the transcripts of the
`
`testimony in related Cases IPR2015-00902 and -00903 of Dr. Paul Laskar
`
`(Ex. 2114) and Dr. Jayne Lawrence (Ex. 2316), portions of Patent Owner’s
`
`Response (Papers 22 and 23); and portions of the declarations of Drs. Adam
`
`C. Myers (Ex. 2126), Daryl S. Paulson (Ex. 2128), Robert O. Williams (Ex.
`
`
`
` 5
`
` In this Decision, we reference only citations to exemplary papers filed in
`IPR2015-01100. Exhibit numbers are the same in each captioned
`proceeding.
`
`
`
`2
`
`

`

`IPR2015-01097 (Patent 8,754,131 B2)
`IPR2015-01100 (Patent 8,927,606 B1)
`IPR2015-01105 (Patent 8,871,813 B2)
`
`2082), Stephen G. Davies (Ex. 2105), William B. Trattler (Ex. 2116), and
`
`John C. Jarosz (Ex. 2130) that cite or substantially describe the above
`
`categories of documents sought to be sealed. Mot. 1. Patent Owner asserts
`
`that Petitioner does not oppose the motion. Id. at 2.
`
`The Amended Proposed Stipulated Protective Order (“proposed
`
`order”) differs from the Board’s default protective order set forth in the
`
`Office Patent Trial Practice Guide (“Trial Practice Guide”), 77 Fed. Reg.
`
`48,756, 48,771 (Aug. 14, 2012) in a number of ways, such as including two
`
`additional categories of confidential information, i.e., “PROTECTIVE
`
`ORDER MATERIAL – BOARD’S EYES ONLY” and “PROTECTIVE
`
`ORDER MATERIAL – FED R. EVID 615.” Mot. 1, App’x A at 2; see
`
`Paper 32 (redlined version of the proposed order showing modifications to
`
`the Board’s default protective order).
`
`For the reasons described in the following discussion, we deny the
`
`Motion to Seal and we deny entry of the proposed order without prejudice.
`
`II. DISCUSSION
`
`A. Proposed Order
`
`When a party seeks entry of a protective order that differs from the
`
`default protective order set forth in the Trial Practice Guide, it is essential
`
`that the modifications made and the effect of those modifications are clear.
`
`Based upon our review, the proposed order is not in an adequate form for
`
`entry. In particular, the proposed order recites variations of the term “party”
`
`with apparently different meanings. In some instances the term refers to
`
`either Petitioner or Patent Owner. For example, the proposed order states
`
`“Nothing in this Order prevents any Party from challenging a confidentiality
`
`
`
`3
`
`

`

`IPR2015-01097 (Patent 8,754,131 B2)
`IPR2015-01100 (Patent 8,927,606 B1)
`IPR2015-01105 (Patent 8,871,813 B2)
`
`designation to any Exhibit by raising the matter with the Board.” Id. at 5
`
`n.2. In other instances, the term is defined in a manner that apparently
`
`excludes the Petitioner in the captioned cases, i.e., “(A) Parties. Persons
`
`who are owners of a patent involved in the proceeding and other persons
`
`who are identified as a real party-in-interest in any Related Proceeding.” Id.
`
`at 4, 6. Those inconsistencies create an ambiguity in the proposed order that
`
`prevents us from entering it.
`
`Further, the proposed order includes a category of confidential
`
`information that may be marked as “PROTECTIVE ORDER MATERIAL –
`
`FED R. EVID. 615.” It is unclear whether that category of confidential
`
`information is necessary at this stage in the proceeding because the
`
`discovery phase has concluded. If the parties determine that such category is
`
`still necessary, that need should be explained. Also, the proposed order
`
`states that such disclosures shall not occur “until after such time as the Board
`
`has lifted the Rule on Witnesses under Fed. R. Evid. 615 ….” Id. at 3. We
`
`do not contemplate, however, “lift[ing] the Rule on Witnesses.” Rather, the
`
`proposed order should describe sufficiently when and/or under what
`
`circumstances the disclosure restriction shall expire, if that is the intent of
`
`the parties, without requiring an additional order by the panel. Similarly,
`
`after an expiration of the Fed. R. Evid. 615 disclosure restriction, any
`
`request to disclose such material to an expert should not be made contingent
`
`“upon the formal request of any Party to the Board or upon a joint request by
`
`the Parties to the Board’s administrative staff.” See id. at 4. Such requests,
`
`if required, should be directed to the party from whom the disclosure is
`
`sought.
`
`
`
`4
`
`

`

`IPR2015-01097 (Patent 8,754,131 B2)
`IPR2015-01100 (Patent 8,927,606 B1)
`IPR2015-01105 (Patent 8,871,813 B2)
`
`
`Additionally, rather than reciting that nothing in the proposed order
`
`“shall amend or alter the Stipulated Discovery Confidentiality Order” filed
`
`in the cited district court litigation, we recommend that provision state, more
`
`precisely, that the proposed order shall apply only to the captioned
`
`proceedings.
`
`The parties are reminded that information subject to a protective order
`
`will become public if identified in a final written decision in this proceeding,
`
`and that a motion to expunge the information will not necessarily prevail
`
`over the public interest in maintaining a complete and understandable file
`
`history. See Office Patent Trial Practice Guide, 77 Fed. Reg. 48,756, 48,761
`
`(Aug. 14, 2012).
`
`B. Motion to Seal
`
`“There is a strong public policy for making all information filed in a
`
`quasi-judicial administrative proceeding open to the public, especially in an
`
`inter partes review which determines the patentability of claims in an issued
`
`patent and therefore affects the rights of the public.” Garmin Int’l v. Cuozzo
`
`Speed Techs., LLC, IPR2012-00001, slip op. at 1–2 (PTAB Mar. 14, 2013)
`
`(Paper 34). A motion to seal may be granted for good cause. 37 C.F.R. §
`
`42.54. The moving party bears the burden of showing that there is good
`
`cause for the relief requested, including why the information is appropriate
`
`to be filed under seal. 37 C.F.R. §§ 42.20, 42.54. The Office Patent Trial
`
`Practice Guide notes that 37 C.F.R. § 42.54 identifies confidential
`
`information in a manner consistent with Federal Rule of Civil Procedure
`
`26(c)(1)(G), which provides for protective orders for trade secret or other
`
`confidential research, development, or commercial information. 77 Fed.
`
`
`
`5
`
`

`

`IPR2015-01097 (Patent 8,754,131 B2)
`IPR2015-01100 (Patent 8,927,606 B1)
`IPR2015-01105 (Patent 8,871,813 B2)
`
`Reg. at 48,760. Until a motion to seal is decided, documents filed with the
`
`motion shall be sealed provisionally. 37 C.F.R. § 42.14.
`
`Patent Owner requests that we seal four categories of exhibits and
`
`portions of its Patent Owner Response and supporting declarations citing or
`
`describing those exhibits. Mot. 7.
`
`As discussed, we have denied entry of the proposed order without
`
`prejudice. Thus, the motion to seal is also denied without prejudice, as it is
`
`based upon an unacceptable protective order. Under the circumstances, we
`
`exercise our discretion to maintain the papers and exhibits cited by Patent
`
`Owner under a provisional seal, in the manner requested, through July 31,
`
`2016, to (a) permit Patent Owner and Petitioner to resolve the issues that we
`
`have identified regarding the proposed order in an amended proposed order,
`
`and (b) allow Patent Owner an opportunity to file a revised motion to seal
`
`after a protective order is entered in this proceeding or to withdraw
`
`provisionally sealed papers and exhibits. In a revised motion to seal, Patent
`
`Owner should consider and address the following:
`
`1. Patent Owner’s NDA and Filings Citing the NDA
`
`Patent Owner asserts that Exhibits 2096, 2102, 2103, 2110, 2251, and
`
`2291–2293 represent excerpts from Patent Owner’s NDA and should be
`
`sealed in their entirety as “PROTECTIVE ORDER MATERIAL –
`
`BOARD’S EYES ONLY.” Mot. 7. Patent Owner explains that its NDA
`
`was filed confidentially with the Food and Drug Administration. Id.
`
`According to Patent Owner, “public disclosure of the contents of these
`
`documents, or descriptions of those contents, would disclose confidential
`
`business terms in a highly competitive market.” Id. at 9. Patent Owner
`
`
`
`6
`
`

`

`IPR2015-01097 (Patent 8,754,131 B2)
`IPR2015-01100 (Patent 8,927,606 B1)
`IPR2015-01105 (Patent 8,871,813 B2)
`
`asserts also that “redaction of those exhibits would not be practical.” Id. at
`
`8.
`
`Patent Owner asserts that those exhibits containing excerpts of the
`
`NDA are cited or substantially described on pages 2, 3, 46–48, and 50 of the
`
`Patent Owner’s Response (Paper 22), in paragraphs 12, 15, 16, 18, and 22 of
`
`Dr. Myers declaration (Ex. 2126), paragraphs 60, 173, 174, 197, 198, 200,
`
`201, and 232–234 of Dr. Williams’ declaration (Ex. 2082), paragraphs 16,
`
`40, 49, and 50 of Dr. Trattler’s declaration (Ex. 2116), and paragraphs 18,
`
`50, 81, 84, and 148 of Dr. Jarosz’ declaration (Ex. 2130). Mot. 7–8. Thus,
`
`Patent Owner requests that those portions of the Patent Owner’s Response
`
`and supporting declarations be sealed as “PROTECTIVE ORDER
`
`MATERIAL – BOARD’S EYES ONLY.” Id. at 9.
`
`
`
`We note that a portion of Exhibit 2096 contains material that Patent
`
`Owner has not established to be confidential. See Ex. 2096, 1. Although the
`
`exhibit represents an excerpt of Patent Owner’s NDA, page 1 does not
`
`appear to contain any confidential or proprietary information. Indeed, that
`
`page appears to contain information readily available to the public.
`
`Additionally, we note that the entirety of Exhibit 2293 lacks any content.
`
`Every page of that exhibit is essentially blank, containing only a portion of
`
`an empty grid. In a revised motion to seal, if Patent Owner continues to seek
`
`to have those exhibits sealed, those issues should be addressed.
`
`2. Research and Development Presentations and the Testimony of
`Ms. Valorie and Dr. Jarosz
`
`Patent Owner asserts that Exhibits 2220, 2226, and 2296 are
`
`presentations containing “Patent Owner’s proprietary information related to
`
`
`
`7
`
`

`

`IPR2015-01097 (Patent 8,754,131 B2)
`IPR2015-01100 (Patent 8,927,606 B1)
`IPR2015-01105 (Patent 8,871,813 B2)
`
`Patent Owner’s methods of conducting confidential discussion groups and
`
`market information for its commercial embodiment of the Patents-at-Issue”
`
`in this and related proceedings. Mot. 10. Patent Owner asserts that the
`
`testimony of Ms. Valorie, an officer of Patent Owner’s parent company
`
`(Ex. 2258) also “relate[s] to Patent Owner’s commercial embodiment of the
`
`patent at issue.” Id. Additionally, Patent Owner asserts that those materials
`
`are relied upon in the declaration of Dr. Jarosz (Exhibit 2130 ¶¶ 13, 40, 42,
`
`50, 68, 81, and 98–101) and in the Patent Owner Response. Thus, Patent
`
`Owner requests for those items to be sealed as “PROTECTIVE ORDER
`
`MATERIAL.” Id. at 11.
`
`We note that Patent Owner has not identified what portions of its
`
`Patent Owner’s Response contain the asserted confidential material, i.e., the
`
`portions of that filing that it seeks to seal. In that respect, the motion to seal
`
`is deficient. Further, we note that Exhibit 2258 contains seven inconsecutive
`
`pages from a transcript of the deposition of Ms. Tracy Valorie. The first
`
`page of the exhibit is the cover sheet and the second page includes little
`
`more than an introduction of the counsel, the videographer, and the witness
`
`present at the deposition. In other words, Patent Owner has not established
`
`that the exhibit should be sealed in its entirety by asserting only that the
`
`testimony is “related to Patent Owner’s commercial embodiment of the
`
`patent at issue.” Mot. 10. In a revised motion to seal, if Patent Owner
`
`continues to seek to have those materials sealed, those issues should be
`
`addressed.
`
`
`
`8
`
`

`

`IPR2015-01097 (Patent 8,754,131 B2)
`IPR2015-01100 (Patent 8,927,606 B1)
`IPR2015-01105 (Patent 8,871,813 B2)
`
`
`3. Third Party Testing Reports and Test Methods
`
`Patent Owner seeks to seal Exhibits 2267–2278, 2286, and 2294 as
`
`“PROTECTIVE ORDER MATERIAL.” Mot. 12. Patent Owner asserts that
`
`those exhibits are “confidential materials of third parties BioScience and
`
`SSCI.” Mot. 11. According to Patent Owner, those exhibits “contain third
`
`party BioScience’s and SSCI’s proprietary information related to each
`
`company’s proprietary testing methods.” Id. Patent Owner asserts that “the
`
`public’s interest in the instant proceeding does not outweigh a third party’s
`
`interest in protecting this limited sensitive business information.” Id. Those
`
`assertions are insufficient. In particular, Patent Owner has neither
`
`demonstrated that the exhibits contain proprietary information nor
`
`established its standing to assert the “interest” of a non-party third party in
`
`this proceeding. Patent Owner’s request to seal portions of the declaration
`
`of Dr. Paulson (Ex. 2128 ¶¶ 10, 14, 17–18, and 20–25) that cite those
`
`exhibits to document preservative effectiveness testing that BioScience
`
`performed on samples of Patent Owner’s commercial product is problematic
`
`for the same reason. In a revised motion to seal, if Patent Owner continues
`
`to seek to have those materials sealed, those issues should be addressed.
`
`4. The Testimony of Dr. Lawrence and Filings citing that Testimony
`
`Patent Owner requests that the transcript of Dr. Jayne Lawrence’s
`
`deposition testimony in this proceeding be sealed in its entirety under
`
`Federal Rule of Evidence 615 (“FRE 615”) “until such time as the cross
`
`examination of Petitioner InnoPharma’s expert Dr. Paul Laskar in
`
`connection with InnoPharma’s petitions in the Related IPR Proceedings have
`
`been concluded.” Mot. 12. As discussed with respect to the proposed order,
`
`
`
`9
`
`

`

`IPR2015-01097 (Patent 8,754,131 B2)
`IPR2015-01100 (Patent 8,927,606 B1)
`IPR2015-01105 (Patent 8,871,813 B2)
`
`this request appears to be moot at this stage in the proceeding, as discovery
`
`has concluded. Similarly, Patent Owner’s request to seal portions of Patent
`
`Owner’s Response and the declarations of Drs. Williams and Dr. Davies that
`
`cite or substantially describe Dr. Lawrence’s or Dr. Laskar’s testimony for
`
`the same duration appears to be moot. Mot. 13–14. In a revised motion to
`
`seal, if Patent Owner contends otherwise, it should explain that position.
`
`ORDER
`
`In accordance with the foregoing, it is hereby:
`
`ORDERED that Patent Owner’s Motion to Seal is denied without
`
`prejudice and entry of the Amended Proposed Stipulated Protective Order is
`
`denied without prejudice;
`
`FURTHER ORDERED that Exhibits 2082, 2096, 2102, 2103, 2105,
`
`2110, 2114, 2116, 2126, 2128, 2130, 2220, 2226, 2251, 2267–2278, 2286,
`
`2291–2294, 2296, 2316, as well as, Papers 22 and 23 shall remain
`
`provisionally sealed until further notice by the Board;
`
`FURTHER ORDERED that Patent Owner may file a motion for entry
`
`of either the default protective order or a second amended protective order
`
`addressing the issues set forth in this Decision on or before July 31, 2016;
`
`FURTHER ORDERED that Patent Owner may file a revised motion
`
`to seal addressing the issues set forth in this Decision, and/or withdraw
`
`provisionally sealed exhibits on or before July 31, 2016; and
`
`FURTHER ORDERED that any opposition to a proposed protective
`
`order and/or revised motion to seal shall be filed within 5 business days after
`
`the filing of the motion(s).
`
`
`
`10
`
`

`

`IPR2015-01097 (Patent 8,754,131 B2)
`IPR2015-01100 (Patent 8,927,606 B1)
`IPR2015-01105 (Patent 8,871,813 B2)
`
`PETITIONERS:
`
`Deborah Yellin
`DYellin@crowell.com
`
`Jonathan Lindsay
`JLindsay@crowell.com
`
`Teresa Rea
`trea@crowell.com
`
`Jitendra Malik
`jitty.malik@alston.com
`
`Bryan Skelton
`bryan.skelton@alston.com
`
`
`
`PATENT OWNER:
`
`Bryan Diner
`bryan.diner@finnegan.com
`
`Justin Hasford
`justin.hasford@finnegan.com
`
`Joshua Goldberg
`joshua.goldberg@finnegan.com
`
`
`
`
`
`11
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket